MCID: MRK002
MIFTS: 34

Marek Disease

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Marek Disease

MalaCards integrated aliases for Marek Disease:

Name: Marek Disease 50 69
Neurolymphomatosis 50 56
Marek's Disease 50
Fowl Paralyses 50
Fowl Paralysis 50

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA206586

Summaries for Marek Disease

MalaCards based summary : Marek Disease, also known as neurolymphomatosis, is related to lymphoma and retinal arteries, tortuosity of. An important gene associated with Marek Disease is HMGCR (3-Hydroxy-3-Methylglutaryl-CoA Reductase), and among its related pathways/superpathways are Glucocorticoid receptor regulatory network and MAPK Signaling: Oxidative Stress Pathway. The drugs Selenium and Nitroglycerin have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and heart, and related phenotype is liver/biliary system.

Wikipedia : 72 Marek\'s disease is a highly contagious viral neoplastic disease in chickens. It is named after József... more...

Related Diseases for Marek Disease

Graphical network of the top 20 diseases related to Marek Disease:



Diseases related to Marek Disease

Symptoms & Phenotypes for Marek Disease

MGI Mouse Phenotypes related to Marek Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 8.92 ACE HMGCR JUN TP53

Drugs & Therapeutics for Marek Disease

Drugs for Marek Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Vet_approved Phase 4 7782-49-2
2
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
3
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
4
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
5
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
6 Antimetabolites Phase 4,Phase 2
7 Hypolipidemic Agents Phase 4,Phase 3
8 Lipid Regulating Agents Phase 4
9 Antioxidants Phase 4
10 Micronutrients Phase 4,Phase 3
11 Protective Agents Phase 4,Phase 2
12 Trace Elements Phase 4,Phase 3
13 Adrenergic beta-Antagonists Phase 4
14 Diuretics, Potassium Sparing Phase 4
15 Sodium Channel Blockers Phase 4
16 Autonomic Agents Phase 4,Phase 3,Phase 2
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
19 Adrenergic Agents Phase 4
20 Adrenergic Antagonists Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Antihypertensive Agents Phase 4,Phase 3
23 Vasodilator Agents Phase 4
24 Adrenergic Agonists Phase 4
25 Adrenergic beta-1 Receptor Antagonists Phase 4
26 Adrenergic beta-Agonists Phase 4
27 Sympatholytics Phase 4
28 Anticholesteremic Agents Phase 4
29 Calcium, Dietary Phase 4
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
31 Rosuvastatin Calcium Phase 4 147098-20-2
32
Fluorouracil Approved Phase 3 51-21-8 3385
33
Heroin Approved, Illicit Phase 3 561-27-3 5462328
34
Methadone Approved Phase 3,Phase 2 76-99-3 4095
35
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
36
Rivaroxaban Approved Phase 3 366789-02-8
37
Adalimumab Approved Phase 3 331731-18-1 16219006
38
Citalopram Approved Phase 3 59729-33-8 2771
39
Norepinephrine Approved Phase 3 51-41-2 439260
40
Sertraline Approved Phase 3 79617-96-2 68617
41
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
42
Ramipril Approved Phase 3 87333-19-5 5362129
43
chenodeoxycholic acid Approved Phase 3 474-25-9 10133
44
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
45
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2 16590-41-3 5360515
46
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
47
Cholecalciferol Approved, Nutraceutical Phase 3 67-97-0 6221 10883523 5280795
48
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
50 tannic acid Approved, Nutraceutical Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 70)

id Name Status NCT ID Phase Drugs
1 Selenium Supplementation in Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT00186706 Phase 4 Selenium
2 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Completed NCT01425359 Phase 4 Ranolazine;Ranolazine placebo
3 ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients Completed NCT01323764 Phase 4
4 Effects of Brain Beta-Amyloid on Postoperative Cognition Recruiting NCT01606488 Phase 4 Florbetapir F 18 (18F-AV-45)
5 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
6 Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients? Terminated NCT01605370 Phase 4 Nebivolol;Metoprolol succinate
7 Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients Terminated NCT00673582 Phase 4 Rosuvastatin;Placebo
8 Preoperative Radiotherapy and Local Excision in Rectal Cancer Unknown status NCT00738790 Phase 3
9 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
10 A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Completed NCT01158560 Phase 3
11 A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure Recruiting NCT01877915 Phase 3 Rivaroxaban;Placebo
12 BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Recruiting NCT02871635 Phase 3 BI 695501;HUMIRA
13 A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT02394028 Phase 3 Etrolizumab 210 mg;Etrolizumab 105 mg;Placebo
14 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3 etrolizumab
15 A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression Recruiting NCT02782104 Phase 3 Intranasal Esketamine
16 A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Recruiting NCT02493868 Phase 3 Esketamine;Placebo;Duloxetine (Oral Antidepressant);Escitalopram (Oral antidepressant);Sertraline (Oral Antidepressant);Venlafaxine Extended Release (XR) (Oral Antidepressant)
17 Secondary Prevention of Cardiovascular Disease in the Elderly Trial Recruiting NCT02596126 Phase 3 Cardiovascular Polypill;Treatment Prevention for Secondary CV
18 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
19 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3 Etrozulimab;Placebo
20 Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Active, not recruiting NCT01389167 Phase 3 Vivitrol;Naltrexone (oral)
21 MSB11022 in Moderate to Severe Rheumatoid Arthritis Active, not recruiting NCT03052322 Phase 3 MSB11022;Humira®
22 The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Terminated NCT01975376 Phase 3 bococizumab (PF-04950615);Placebo
23 Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer Unknown status NCT01195298 Phase 2 Capecitabine and Bevacizumab
24 Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression Completed NCT00134784 Phase 2 [123I]B-CIT SPECT imaging
25 Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families Completed NCT00273351 Phase 2 [123I]B-CIT
26 A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease Completed NCT00117819 Phase 2 [123I]ß CIT and SPECT imaging
27 Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease Completed NCT01137526 Phase 2 ABT-384;donepezil;placebo
28 Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome Completed NCT00132626 Phase 2
29 Brief Introductory Therapy for Opioid Dependence Completed NCT00406484 Phase 2
30 0.5M Na Lactate Solution in Acute Heart Failure (AHF) Completed NCT01981655 Phase 2 0.5M Sodium lactate;Hartmann's solution
31 R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas Completed NCT00558220 Phase 2
32 SUBLIVAC FIX Phleum Pratense DT/DRF Completed NCT01682070 Phase 2
33 Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Recruiting NCT01141023 Phase 2 Datscan and AV-133
34 Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders Recruiting NCT02722993 Phase 2
35 Remote Ischemic Preconditioning of Human Myocardium Recruiting NCT01994707 Phase 2
36 Patient Driven Recovery With Nalmefene and Coaching Recruiting NCT03279562 Phase 2 Nalmefene
37 Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI) Recruiting NCT02743949 Phase 2 Vonoprazan;Esomeprazole;Esomeprazole Placebo
38 Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone Recruiting NCT02640534 Phase 2 Enzalutamide;Metformin
39 A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Active, not recruiting NCT00875667 Phase 2 Lenalidomide;Investigators choice single agent
40 A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging Terminated NCT01264861 Phase 2 Safinamide
41 Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Completed NCT01908010 Phase 1 ABT-354;ABT-354;Placebo
42 Study of IRX4204 for Treatment of Early Parkinson's Disease Completed NCT02438215 Phase 1 IRX4204
43 Home Care Medication Management Program for the Frail Elderly Completed NCT01321853 Phase 1
44 Should we Repair Ischemic Mitral Regurgitation? Unknown status NCT00443365
45 Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy Unknown status NCT00947908
46 Revascularization in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) With Multivessel and/or Unprotected Left Main Coronary Disease Unknown status NCT01311323
47 Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease Unknown status NCT02066272
48 Safety and Efficacy of Canaloplasty and Non-penetrating Deep Sclerectomy With Phacoemulsification to Treat Glaucoma and Cataract Unknown status NCT01726543
49 EnSeal Efficacy and Bursting Pressure in Human Vessels Unknown status NCT01312246
50 A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease Completed NCT00117195

Search NIH Clinical Center for Marek Disease

Genetic Tests for Marek Disease

Anatomical Context for Marek Disease

MalaCards organs/tissues related to Marek Disease:

39
T Cells, Brain, Heart, Testes, Liver, Bone, B Cells

Publications for Marek Disease

Articles related to Marek Disease:

id Title Authors Year
1
The 132 bp repeats are present in RNA transcripts from 1.8 kb gene family of Marek disease virus-transformed cells. ( 8105666 )
1993
2
Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. ( 1315048 )
1992
3
The structure of Marek disease virus DNA: the presence of unique expansion in nonpathogenic viral DNA. ( 2983314 )
1985
4
Extensive homology exists between Marek disease herpesvirus and its vaccine virus, herpesvirus of turkeys. ( 6328512 )
1984
5
Inverted repeat nucleotide sequences in the genomes of Marek disease virus and the herpesvirus of the turkey. ( 6281774 )
1982

Variations for Marek Disease

Expression for Marek Disease

Search GEO for disease gene expression data for Marek Disease.

Pathways for Marek Disease

GO Terms for Marek Disease

Biological processes related to Marek Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.58 JUN TNFRSF8 TP53
2 positive regulation of apoptotic process GO:0043065 9.43 JUN TNFRSF8 TP53
3 Ras protein signal transduction GO:0007265 9.37 JUN TP53
4 positive regulation of smooth muscle cell proliferation GO:0048661 9.32 HMGCR JUN
5 positive regulation of neuron apoptotic process GO:0043525 9.16 JUN TP53
6 protein tetramerization GO:0051262 8.96 HMGCR TP53
7 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 8.62 JUN TP53

Molecular functions related to Marek Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase 2A binding GO:0051721 8.62 HMGCR TP53

Sources for Marek Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....